MedTrace Logo

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

NCT02240875 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2018-07-06

No results posted yet for this study

Summary

The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses. The study will enable us to assess the safety of the vaccines and the extent of the immune response in healthy volunteers. The investigators will do this by giving volunteers a either one or two vaccinations, doing blood and saliva tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use either of these vaccines in humans. We plan to recruit a total of 92 volunteers to be vaccinated.

Conditions

  • Ebola
  • Ebola Zaire

Interventions

BIOLOGICAL

cAd3-EBO Z at 1 x 10^10 vp

Low dose cAd3-EBO Z

BIOLOGICAL

cAd3-EBO Z at 2.5 x 10^10 vp

Medium dose cAd3-EBO Z

BIOLOGICAL

cAd3-EBO Z at 5 x 10^10 vp

High dose cAd3-EBO Z

BIOLOGICAL

4.4x10^8 TCID50s MVA-BN® Filo

High dose MVA-BN® Filo

BIOLOGICAL

2.2x10^8 TCID50s MVA-BN® Filo

Low dose MVA-BN® Filo

BIOLOGICAL

4.4 x 10^7 TCID50s MVA-BN® Filo

Very low dose MVA-BN® Filo

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • University of Oxford

    lead OTHER

Principal Investigators

  • Adrian V Hill · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-17
Primary Completion
2017-08-22
Completion
2017-08-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02240875 on ClinicalTrials.gov